Drug Legalization Series · Part 21
Drug Legalization Series Part 21: Drug Legalization Is Bipartisan: Political Reality, Not Political Fantasy
If you're new to the series, start here.
DRUG LEGALIZATION SERIES
PART 21
If you’re new to the series, start here.
Drug Legalization Is Bipartisan
Political reality, not political fantasy.
Executive Summary
Most people treat drug legalization like a culture-war identity test.
They assume the “left” wants it because they hate police, and the “right” hates it because they love punishment.
That’s not what is actually happening on the ground anymore.
The U.S. had 79,384 drug overdose deaths in 2024.[1] That number fell sharply from 2023—but it is still mass death as a baseline.[1] And the addiction treatment gap is still brutal: CDC notes that in 2022, 54.6 million people needed substance use treatment, but only 13.1 million received it.[2] Meanwhile, the country continues paying huge public costs for incarceration costs and crisis care—while the illegal market keeps adapting faster than law enforcement can.[3][4]
This is why bipartisan drug policy reform is not only possible. It is increasingly necessary.
This chapter introduces the core claim of the series:
Drug legalization is not endorsement. It is regulation.
And the most viable model is not “one rule for every substance.” The most viable model is risk-based drug regulation, where rules tighten as risk rises, and the highest-risk lane moves through something like a regulated pharmacy model.
This chapter also makes the coalition case in plain language—who benefits and why:
• Left case: lower incarceration, better racial equity, better mental health coverage, and more treatment capacity.
• Right case: fiscal responsibility, personal liberty, less cartel leverage, and less chaos—plus more credible public safety enforcement.
• Insurance case: more medication access, fewer repeat emergencies, and measurable addiction treatment cost savings.
• Law enforcement case: time freed to focus on violence, exploitation, trafficking, and impaired driving; fewer “catch and release” loops; better community trust.
• Treatment infrastructure case: more access, clearer definitions, better outcomes tracking, and funding aligned with results.
• General public case: taxes go toward helping instead of harming, lower long-term tax burden because incarceration costs are expensive, and fewer families destroyed by preventable overdose.
If you want the definitions that keep people arguing past each other, Part 1.5 clarifies legalization vs decriminalization vs regulation.
If you want what regulation “buys” (safety standards and accountability), Part 4 goes deeper on drug legalization benefits.
The Core Problem: Prohibition Didn’t Create Safety—It Created an Unregulated Supply Chain
Call it what it is.
Prohibition did not eliminate drug demand. It outsourced the supply chain to the black market.
That is why dosage is unknown, purity is unknown, contaminants are unknown, and potency shifts without warning. In that environment, bad guesses kill.
This is why “toughness” has not produced safety. It has produced a market where the most ruthless suppliers win and where the public has no quality control tools.
At the same time, criminalization created a second system of harm:
• incarceration costs that taxpayers fund
• felony barriers to employment, housing, and stability
• long-term damage to families and communities
That’s the underclass problem covered in Part 2.
And it’s the civic rights fallout covered in Part 3.
This is the first reason drug legalization benefits are not theoretical. Regulation converts black-market chaos into a governable system with rules, audits, and consequences.
Bipartisan Drug Policy Reform: Why the Coalition Is Real
Here is the political truth that gets missed.
Bipartisan drug policy reform works when it is framed as a systems upgrade, not a morality debate.
If legalization is sold as “stop judging people,” it fails with conservatives and many moderates.
If legalization is sold as “stop arresting everyone,” it fails with people who are watching visible disorder and want public safety restored.
But if legalization is sold as:
• govern the supply chain
• reduce preventable death
• enforce real accountability
• stop wasting money on failure
• expand treatment and mental health care
• reduce cartel power and violence incentives
• protect kids and punish fraud
…then bipartisan drug policy reform becomes plausible.
Here’s how each side can honestly sell it.
Left: incarceration, racial equity, and mental health
A regulated model reduces the centrality of possession arrests and the destruction that follows. A BJS report on racial disparity in U.S. drug arrests documented large differences between drug arrest proportions and self-reported drug use proportions in national survey data.[5] Even though that report is older, the basic lesson remained: punishment systems often hit harder than the behavior distribution alone would predict.[5]
A regulated model also makes it easier to treat addiction like what it is: a treatable condition tied to trauma, poverty, and mental health—not a permanent moral stain. CDC explicitly links stigma to barriers to care and cites the massive treatment gap in 2022.[2]
So for left-leaning voters and lawmakers, drug legalization benefits include:
• fewer people processed into the underclass
• less racially uneven enforcement pressure
• more mental health and addiction treatment coverage
• a public-health approach that reduces stigma and increases care access
Right: fiscal responsibility, personal liberty, and national security leverage
Conservatives and libertarians don’t need to love drug use to support a regulated model.
The right-side argument is:
• The state has no business burning billions on a failing strategy.
• Adults should not be turned into permanent felons for possession when the policy doesn’t even produce safety.
• Enforcement should focus on harm: violence, trafficking, fraud, sales to minors, and impaired driving.
• A regulated system can reduce the profitability of illicit supply chains—especially where demand can be met through audited channels.
Incarceration is not cheap. The Federal Register reported that based on FY 2023 data, the average annual cost of incarceration fee for a federal inmate was $44,090.[6] That’s before counting the economic damage of lost work, family disruption, and downstream instability.
That is why the fiscal case is not hypothetical. It is arithmetic. Addiction treatment cost savings are real; NIH summarizes that studies show every $1 spent on substance use disorder treatment saves $4 in health care costs and $7 in criminal justice costs.[7]
Personal liberty is also real. The right does not need to endorse drug use to oppose a government strategy that keeps failing while creating permanent criminal records.
Immigration and global politics are part of the right’s argument too. DEA’s National Drug Threat Assessment emphasizes the threat to public safety and national security posed by trafficking networks and synthetic drugs like fentanyl.[8] CBP publishes drug seizure statistics, including fentanyl, reflecting the scale of cross-border enforcement activity.[9]
A regulated domestic framework does not magically end trafficking. But it can reduce the size of the market that traffickers profit from—especially when paired with treatment expansion and a focus on the highest-risk population.
So for the right, drug legalization benefits include:
• fiscal responsibility: lower incarceration costs and lower crisis spending
• personal liberty: fewer lives ruined by possession felonies
• law-and-order credibility: enforcement refocused on violence and exploitation
• reduced cartel leverage where demand is shifted into regulated channels
That’s the coalition logic. Not fantasy. Political reality.
Stakeholders: Why This Is Good for Insurance, Law Enforcement, Providers, and Taxpayers
This is where bipartisan drug policy reform stops being theory and becomes practical.
Insurance: addiction treatment cost savings and fewer repeat crises
Insurance companies and state Medicaid programs already pay for the worst possible version of addiction care: repeated emergency care, repeated hospitalization, repeated detox cycles, and repeated relapse without continuity.
The fiscal argument is straightforward:
• Treatment costs money.
• Crisis care costs more.
• Incarceration costs a lot.
• A stable pathway into medication for opioid use disorder and recovery support costs less than rotating through crisis systems.
NIH summarizes research showing every $1 spent on substance use disorder treatment saves $4 in health care costs and $7 in criminal justice costs.[7] That’s the cleanest headline for addiction treatment cost savings.
So an insurance-friendly reform platform focuses on:
• rapid medication initiation
• continuity after nonfatal overdose
• lower emergency utilization over time
• measurable improvements in outcomes tracking
Law enforcement: focus on real crime, less catch-and-release
Drug enforcement has consumed massive resources while leaving communities with both overdose and disorder.
FBI UCR data for 2019 showed drug abuse violations accounted for the highest number of arrests—estimated at 1,558,862 arrests.[10] That is a huge volume of law enforcement attention.
A regulated model reduces the “catch and release” loop for possession and shifts enforcement toward:
• violence and coercion
• trafficking outside regulated channels
• sales to minors
• fraud and adulteration
• impaired driving
That shift improves public safety and improves community legitimacy. People cooperate more with police when they don’t suspect every encounter will ruin their life for low-level possession.
This ties directly into Part 10 on accountability: legalization does not eliminate consequences; it changes what gets enforced.
Treatment infrastructure: more access plus standardized outcomes tracking
Providers need two things to succeed:
• more clients can actually reach services
• funding follows outcomes rather than paperwork
That means treatment on demand instead of referral theater.
It also means standardized definitions so we can measure what happens. NIH’s HEAL Initiative maintains a Common Data Elements program aimed at harmonizing data collection, including substance use screening elements.[11] NIDA’s Clinical Trials Network also operates a Common Data Elements portal for substance use disorders.[12] Those are practical tools for outcomes tracking across systems.
The point isn’t academic purity. It’s governance.
If a state funds treatment without standardized outcomes tracking, it can’t prove what works and can’t scale what works.
General public: taxes, stability, and helping people you actually know
The public is tired of paying for failure twice:
• first through incarceration costs
• then through emergency care, homelessness systems, and neighborhood disorder
A regulated approach can redirect money from punishment into treatment, prevention, and enforcement against actual harm, not possession. Part 7 makes the “no new taxes” and funding-protection argument through a recovery lockbox concept.
That is the public interest: use existing spending more intelligently, reduce the long-run tax burden by reducing the need for expensive incarceration and crisis response, and start helping friends, neighbors, and family members who clearly need help.
Risk-Based Drug Regulation: The Only Model That Can Survive the Politics
If legalization is framed as one giant switch—legal or illegal—it will keep failing politically.
That’s because different drugs carry different risks.
The only workable political and operational model is risk-based drug regulation.
That phrase matters, and it needs to be said clearly: risk-based drug regulation.
It means:
• lower-risk substances can be governed through licensed retail channels with strict age limits, labeling, and enforcement
• higher-risk substances require tighter controls, tighter monitoring, and clinical pathways
• the highest-risk lane requires the most structure, not the least
This is not a theory. It’s how every other safety domain works. The higher the risk, the tighter the rules.
Part 9 goes deep on what risk-based drug regulation looks like in practice.
If you want “why regulation is better than prohibition,” Part 4 goes deep on the safety and accountability benefits.
This is where bipartisan drug policy reform becomes viable:
• the left can support harm reduction, treatment expansion, and fewer possession felonies
• the right can support tough enforcement against fraud, violence, and sales to minors
• everyone can support “tight rules for high risk, tight accountability everywhere”
It also keeps the coalition stable because it answers the public fear: “What about the worst drugs?”
That’s the next section.
Regulated Pharmacy Model: The High-Risk Lane That Makes the Whole System Passable
The hardest drug policy conversation is always the same.
People ask: what about fentanyl? what about meth? what about the substances that kill?
A serious answer can’t be “open retail.” It also can’t be “keep prohibition and hope.”
This is where the regulated pharmacy model matters.
In this series, the regulated pharmacy model is not a free-for-all. It is a high-structure clinical lane designed for the highest-risk population and the highest-risk substances.
It should include:
• strict eligibility
• standardized product and dosing controls
• auditing and documentation
• tight diversion control
• immediate treatment on demand pathways
• penalties for fraud, coercion, or trafficking
The big political benefit is this: the regulated pharmacy model gives the public a structure they can recognize.
People already understand regulated pharmacies as controlled environments. They already understand age limits, ID checks, licensing, audits, and discipline for violations.
That is why the regulated pharmacy model makes risk-based drug regulation politically survivable. It lets reformers say: high risk gets high structure.
Part 14 is the full deep dive on the regulated pharmacy model.
This is also where law enforcement gets a cleaner mission: focus on the illegal market outside the regulated lane, especially violence, coercion, adulteration, and sales to minors.
That is what accountability looks like under regulation.
And yes, diversion control is real. That is why the architecture includes audits and enforcement. A model without diversion control is not a model. It’s negligence.
The Money and Measurement Case: Addiction Treatment Cost Savings With Outcomes Tracking
One reason drug policy reform stays broken is that spending is disconnected from outcomes.
We spend on arrests. We spend on jails. We spend on emergency rooms. We spend on overdoses—then call it tradition.
A coherent system spends on what reduces harm.
Start with the simplest fiscal argument: addiction treatment cost savings.
NIH summarizes research showing every $1 spent on substance use disorder treatment saves $4 in health care costs and $7 in criminal justice costs.[7] That is the financial story for insurers, taxpayers, and budget conservatives.
Now add outcomes tracking.
If we want to fund what works, we need standard ways to measure what “works” means.
That includes definitions and metrics:
• initiation: how fast did someone get into care after requesting help?
• retention: are they still engaged at 30/90/180 days?
• stability: are overdoses declining among participants?
• relapse/lapse measurement: are we using consistent definitions and consistent tracking tools?
• system outcomes: are emergency visits dropping? are jail bookings dropping?
NIH’s HEAL Initiative Common Data Elements program and NIDA’s Clinical Trials Network Common Data Elements portal both exist because standardized measures matter when systems want comparable outcomes.[11][12]
This is the treatment infrastructure argument the public rarely hears: standardized outcomes tracking is what allows policy evaluation and funding discipline.
That is how you build a “fund the wins” culture instead of a “fund the talking points” culture.
Public Safety and Accountability: What Still Gets Enforced
This chapter is not a plea for permissiveness.
A regulated model is stricter where it matters.
It still enforces:
• unlicensed trafficking
• sales to minors
• fraud and mislabeling
• contamination and adulteration
• violence, coercion, exploitation
• impaired driving
That is the public safety argument. It satisfies people who are tired of chaos.
It also satisfies law enforcement by giving them a mission aligned with real harm, not a mission aligned with arrest volume.
Part 10 is the full accountability chapter.
Meanwhile, Part 5 covers how prohibition markets produce violence incentives.
That’s part of the right’s global politics argument too. DEA’s threat assessment frames trafficking organizations and synthetic drugs as a public safety and national security threat.[8] And CBP’s seizure reporting reflects the ongoing enforcement effort at the border.[9]
Regulation doesn’t eliminate the need for enforcement. It makes enforcement smarter.
The Bottom Line
This Part 21 is not asking anyone to pretend drug use is good.
It is asking people to stop pretending prohibition is still solving the problem.
A regulated model is viable for both parties because it trades a failing approach for measurable governance:
• fewer possession felonies and fewer ruined lives (left and liberty-minded right)
• better racial equity outcomes compared to blanket criminalization pressure (left)
• lower incarceration costs and lower crisis-consequence spending (right and taxpayers)
• real addiction treatment cost savings with outcomes tracking (insurers and budget hawks)
• a risk-tier structure the public can understand (everyone)
• public safety enforcement aimed at harm, not symbolism (everyone)
• a regulated pharmacy model to manage the high-risk lane (everyone who fears chaos)
That is bipartisan drug policy reform in plain English: not a fantasy, not a slogan, not a purity test.
A system upgrade.
Frequently Asked Questions
Is bipartisan drug policy reform actually realistic right now?
Yes—if it is framed as public safety plus fiscal responsibility plus treatment access, not as an ideological victory lap. Public opinion data on marijuana legalization shows broad support across party groups, which is one signal that “regulated systems” are no longer automatically toxic.[13][14]
Do drug legalization benefits apply to all drugs equally?
No. That’s why risk-based drug regulation matters. Different substances require different access lanes and different safeguards. One rule for every substance fails in practice.
What is the regulated pharmacy model in one sentence?
The regulated pharmacy model is a high-structure, audited clinical lane for the highest-risk drugs and highest-risk users, designed to reduce overdose risk while maintaining diversion control and accountability.
Why emphasize addiction treatment cost savings?
Because budgets are real. NIH summarizes research showing large cost offsets from treatment spending, including health care and criminal justice savings.[7] That matters to taxpayers, insurers, and conservative policymakers.
How does this help law enforcement?
By reducing arrest volume for low-level possession and allowing a shift toward violence, fraud, trafficking, sales to minors, and impaired driving—what most people actually mean when they say public safety.
References
[1] CDC National Center for Health Statistics. Drug Overdose Deaths in the United States, 2023–2024 (NCHS Data Brief No. 549). https://www.cdc.gov/nchs/products/databriefs/db549.htm
[2] CDC. Stigma Reduction | Stop Overdose (includes 2022 treatment need vs treatment received). https://www.cdc.gov/stop-overdose/stigma-reduction/index.html
[3] CDC. Lifesaving Naloxone | Stop Overdose (OTC access context and distribution pathways). https://www.cdc.gov/stop-overdose/caring/naloxone.html
[4] National Institute on Drug Abuse (NIDA). Medications for Opioid Use Disorder. https://nida.nih.gov/research-topics/medications-opioid-use-disorder
[5] Bureau of Justice Statistics (BJS). The Racial Disparity in U.S. Drug Arrests (PDF). https://bjs.ojp.gov/content/pub/pdf/rdusda.pdf
[6] Federal Register. Annual Determination of Average Cost of Incarceration Fee (COIF) (FY 2023). https://www.federalregister.gov/documents/2024/12/06/2024-28743/annual-determination-of-average-cost-of-incarceration-fee-coif
[7] National Institutes of Health (NIH). Societal Benefits of Improved Health (SUD treatment savings summary). https://www.nih.gov/about-nih/impact-nih-research/serving-society/societal-benefits-improved-health
[8] U.S. Drug Enforcement Administration (DEA). 2025 National Drug Threat Assessment (PDF). https://www.dea.gov/sites/default/files/2025-07/2025NationalDrugThreatAssessment.pdf
[9] U.S. Customs and Border Protection (CBP). Drug Seizure Statistics. https://www.cbp.gov/newsroom/stats/drug-seizure-statistics
[10] FBI Uniform Crime Reporting. Persons Arrested (2019) (drug abuse violations arrest estimate). https://ucr.fbi.gov/crime-in-the-u.s/2019/crime-in-the-u.s.-2019/topic-pages/persons-arrested
[11] NIH HEAL Initiative. Common Data Elements (CDEs) Program. https://www.nih.gov/heal/heal-initiative-requirements/data-sharing-policy/common-data-elements-cdes-program
[12] NIDA Clinical Trials Network. CTN Common Data Elements Portal. https://cde.nida.nih.gov/welcome
[13] Pew Research Center. Most Americans favor legalizing marijuana for medical, recreational use (Mar 26, 2024). https://www.pewresearch.org/politics/2024/03/26/most-americans-favor-legalizing-marijuana-for-medical-recreational-use/
[14] Gallup. Grassroots Support for Legalizing Marijuana Hits Record High (Nov 8, 2023). https://news.gallup.com/poll/514007/grassroots-support-legalizing-marijuana-hits-record.aspx